Non-alcoholic Steatohepatitis (NASH) Treatment Market - Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction
   1. Report Overview
2. Non-alcoholic Steatohepatitis (NASH) Treatment - Overview
3. Executive Summary
4. Non-alcoholic Steatohepatitis (NASH) Treatment: Pipeline Assessment
   1. By Stage of Development
   2. By Route of Administration
   3. By Drug Class
   4. By Molecule Type
   5. By Therapy Area / Indication
   6. By Drug Target
   7. By Sponsor
5. Non-alcoholic Steatohepatitis (NASH) Treatment: Company & Drug Profiles
   1. Clinical Stage
      1. Resmetirom – Madrigal Pharmaceuticals, Inc.
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      2. Elafibranor – GENFIT
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      3. Obeticholic Acid – Intercept Pharmaceuticals, Inc.
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      4. Others
   2. Preclinical
      1. Company Overview
      2. Product Description
      3. R&D Status & Development Activities
      4. Mechanism of Action
      5. Molecule Type
      6. Indications
      7. Route of Administration
      8. Funding
6. Non-alcoholic Steatohepatitis (NASH) Treatment: An Overview on Dormant & Discontinued Pipeline Candidates
   1. Overview
   2. Product Description
   3. Reason for Discontinuation
7. Non-alcoholic Steatohepatitis (NASH) Treatment: Additional Key Insights
   1. Epidemiology Overview: Non-alcoholic Steatohepatitis (NASH) Treatment
   2. Current Market Scenario: Non-alcoholic Steatohepatitis (NASH) Treatment Therapeutics
8. Non-alcoholic Steatohepatitis (NASH) Treatment: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.